Araloside C exhibits protective effects against myocardial ischaemia/reperfusion injury^[1].

Araloside C also up-regulates the expression levels of Hsp90 and improved cell viability in hypoxia/reoxygenation-treated H9c2 cardiomyocytes, whereas the addition of 17-AAG, a pharmacologic inhibitor of Hsp90, attenuates Araloside C-induced cardioprotective effect^[1].
Araloside C (0.5-2.5 μM) concentration-dependently improves the functional recovery of the I/R hearts, including increase in the recovery of LVDP, dP/dtmax and heart rate throughout the reperfusion period, although the baseline mechanical parameters with Araloside C were not significantly different compared with those of the control condition^[1].
Araloside C could improve post-ischaemic cell shortening and Ca²⁺ transients from 2 to 8 μM^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

1089.22

C₅₃H₈₄O₂₃

55446-15-6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Min Wang, et al. Protective effects of Araloside C against myocardial ischaemia/reperfusion injury: potential involvement of heat shock protein 90. J Cell Mol Med. 2017 Sep;21(9):1870-1880.